Drug updated on 9/4/2024
Dosage Form | Injection (intravenous; 10 mg/mL) |
Drug Class | Selectin blockers |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated to reduce the frequency of vasoocclusive crises in adults and pediatric patients aged 16 years and older with sickle cell disease.
Latest News
Summary
- Adakveo (crizanlizumab-tmca) is indicated to reduce the frequency of vaso-occlusive crises in adults and pediatric patients aged 16 years and older with sickle cell disease.
- This summary is based on the review of five systematic review(s)/meta-analysis(es). [1-5]
- Crizanlizumab reduced the frequency of vaso-occlusive crises (VOCs) by 45% in the SUSTAIN trial and demonstrated a significant reduction compared to placebo (HR 0.55, 95% credible interval 0.43, 0.69), with a p-value of 0.02.
- Crizanlizumab prolonged the median time to the first and second VOC and was associated with a reduction in all-cause hospitalization days (HR 0.58, 95% credible interval 0.50, 0.68).
- Voxelotor significantly increased hemoglobin levels (p=<0.001) and exhibited potential synergy when combined with L-Glutamine, while the combination of voxelotor and crizanlizumab was antagonistic.
- Pain was the most common adverse event reported across all therapies (crizanlizumab, L-Glutamine, voxelotor).
- Crizanlizumab exhibited a safety profile comparable to placebo, with no significant differences in adverse events or serious adverse events.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Adakveo (crizanlizumab-tmca) Prescribing Information. | 2022 | Novartis Pharmaceuticals Corporation, East Hanover, NJ |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. | 2020 | Blood Advances |
Therapeutic class overview: sickle cell anemia agents. | 2020 | OptumRx |